Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Ano de publicação
Intervalo de ano de publicação
1.
BMC Med Genet ; 9: 3, 2008 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-18205952

RESUMO

BACKGROUND: The Mediterranean island of Sardinia has a strikingly high incidence of the autoimmune disorders Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Furthermore, the two diseases tend to be co-inherited in the same individuals and in the same families. These observations suggest that some unknown autoimmunity variant with relevant effect size could be fairly common in this founder population and could be detected using linkage analysis. METHODS: To search for T1D and MS loci as well as any that predispose to both diseases, we performed a whole genome linkage scan, sequentially genotyping 593 microsatellite marker loci in 954 individuals distributed in 175 Sardinian families. In total, 413 patients were studied; 285 with T1D, 116 with MS and 12 with both disorders. Model-free linkage analysis was performed on the genotyped samples using the Kong and Cox logarithm of odds (LOD) score statistic. RESULTS: In T1D, aside from the HLA locus, we found four regions showing a lod-score > or =1; 1p31.1, 6q26, 10q21.2 and 22q11.22. In MS we found three regions showing a lod-score > or =1; 1q42.2, 18p11.21 and 20p12.3. In the combined T1D-MS scan for shared autoimmunity loci, four regions showed a LOD >1, including 6q26, 10q21.2, 20p12.3 and 22q11.22. When we typed more markers in these intervals we obtained suggestive evidence of linkage in the T1D scan at 10q21.2 (LOD = 2.1), in the MS scan at 1q42.2 (LOD = 2.5) and at 18p11.22 (LOD = 2.6). When all T1D and MS families were analysed jointly we obtained suggestive evidence in two regions: at 10q21.1 (LOD score = 2.3) and at 20p12.3 (LOD score = 2.5). CONCLUSION: This suggestive evidence of linkage with T1D, MS and both diseases indicates critical chromosome intervals to be followed up in downstream association studies.


Assuntos
Diabetes Mellitus Tipo 1/genética , Ligação Genética , Predisposição Genética para Doença , Repetições de Microssatélites/genética , Esclerose Múltipla/genética , Adolescente , Adulto , Criança , Mapeamento Cromossômico , Diabetes Mellitus Tipo 1/complicações , Feminino , Marcadores Genéticos/genética , Haplótipos , Humanos , Masculino , Ilhas do Mediterrâneo , Pessoa de Meia-Idade , Esclerose Múltipla/complicações , Locos de Características Quantitativas , Estatísticas não Paramétricas
2.
Eur J Heart Fail ; 9(3): 320-2, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17029959

RESUMO

Despite usual iron chelating therapy based on desferrioxamine, patients affected by beta-thalassemia major (beta-TM) often develop progressive heart failure caused by myocardial iron overload, which is the leading cause of mortality within the third decade of life. Heart transplantation is a limited therapeutic option, as very often these patients have multi-organ iron deposits and infective complications (particularly hepatitis C), secondary to frequent blood transfusions. We report the case of a 26-year-old male affected by beta-TM with end-stage heart failure, who showed a dramatic improvement in symptoms and myocardial function when a new oral iron chelating agent, deferiprone, was added to standard therapy with desferrioxamine.


Assuntos
Cardiomiopatia Dilatada/tratamento farmacológico , Desferroxamina/uso terapêutico , Quelantes de Ferro/uso terapêutico , Piridonas/uso terapêutico , Talassemia beta/tratamento farmacológico , Adulto , Cardiomiopatia Dilatada/etiologia , Deferiprona , Quimioterapia Combinada , Ferritinas/sangue , Humanos , Masculino , Recuperação de Função Fisiológica , Talassemia beta/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA